Coronary Artery Disease Therapeutics Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

 

Coronary Artery Disease Therapeutics Market
Coronary Artery Disease Therapeutics Market

Coronary Artery Disease (CAD) is a medical illness caused by damaged or diseased blood vessels that supply the heart with blood, nutrients, and oxygen. Coronary heart disease is defined by the accumulation of cholesterol plaque in the arteries, which causes inflammation. The accumulation of plaque gradually narrows the coronary arteries, reducing blood flow to the heart. Shortness of breath and chest pain result from a decrease in blood flow to the heart, which leads to a heart attack following total blockage.

The worldwide coronary artery disease market is divided into two segments: therapy and testing. The market is divided into four therapeutic categories: medicines, surgery, cardiac rehabilitation, and angioplasty. In the near future, the medicine sector is expected to have the greatest market share in the global coronary artery disease market. The global coronary artery disease treatments market is divided into four tests: cardiac catheterization, cardiac CT scan, coronary angiography, and electrocardiogram.

The Coronary Artery Disease Therapeutics Market is competitive and fragmented, with several main participants. Few big firms currently dominate the market in terms of market share. AstraZeneca Plc, Gilead Sciences, Inc, Novartis AG, Pfizer Inc, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V. are among the businesses currently leading the market.

Comments

Popular posts from this blog

Market Share and Revenue Analysis of the Microdermabrasion Devices Market

The Role of the Foodservice Industry in Driving the French Fries Market

The Growing Demand for Healthcare Staffing Market: Trends and Opportunities